검색
Xencor Inc
XNCR관심 목록에 추가
11.220USD
-0.660-5.56%
종가 05/15, 16:00（ET）시세는 15분 지연됩니다
831.87M시가총액
손실P/E TTM
자세한 내용은 Xencor Inc 회사
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Xencor Inc 정보
종목 코드 XNCR
회사 이름Xencor Inc
상장일Dec 03, 2013
CEODahiyat (Bassil I)
직원 수250
유형Ordinary Share
회계 연도 종료Dec 03
주소465 N. Halstead St.
도시PASADENA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호91107
전화16263055900
웹사이트https://xencor.com/
종목 코드 XNCR
상장일Dec 03, 2013
CEODahiyat (Bassil I)
Xencor Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
6.50K
-118.52%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
5.50K
-140.08%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
6.50K
-118.52%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
5.50K
-140.08%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
수익 분석
통화: USD마지막 업데이트: Mon, Apr 6
통화: USD마지막 업데이트: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Royalties
80.28M
63.93%
Milestone
45.30M
36.07%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Royalties
80.28M
63.93%
Milestone
45.30M
36.07%
주식 보유 통계
마지막 업데이트: Sun, May 10
마지막 업데이트: Sun, May 10
주주
주주 유형
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
14.38%
PRIMECAP Management Company
13.94%
BVF Partners L.P.
9.62%
RTW Investments L.P.
9.14%
RA Capital Management, LP
6.39%
기타
46.52%
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
14.38%
PRIMECAP Management Company
13.94%
BVF Partners L.P.
9.62%
RTW Investments L.P.
9.14%
RA Capital Management, LP
6.39%
기타
46.52%
주주 유형
주주
비율
Investment Advisor
54.03%
Investment Advisor/Hedge Fund
32.00%
Hedge Fund
18.37%
Venture Capital
7.44%
Research Firm
5.09%
Individual Investor
1.17%
Pension Fund
0.85%
Bank and Trust
0.38%
Insurance Company
0.03%
기관 주식 보유
마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q4
364
84.79M
119.03%
--
2026Q1
448
94.73M
127.77%
+2.75K
2025Q4
446
84.30M
118.05%
-5.40M
2025Q3
434
80.43M
112.65%
-6.04M
2025Q2
437
81.68M
114.52%
-1.81M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
10.66M
14.54%
+80.73K
+0.76%
Dec 31, 2025
PRIMECAP Management Company
10.22M
13.93%
-456.70K
-4.28%
Dec 31, 2025
BVF Partners L.P.
7.13M
9.73%
+2.51M
+54.43%
Dec 31, 2025
RTW Investments L.P.
6.78M
9.24%
+556.41K
+8.94%
Dec 31, 2025
RA Capital Management, LP
4.74M
6.46%
+4.74M
--
Mar 23, 2026
State Street Investment Management (US)
4.51M
6.15%
+833.42K
+22.69%
Dec 31, 2025
EcoR1 Capital, LLC
3.25M
4.43%
-2.89M
-47.09%
Dec 31, 2025
TCG Crossover Management, LLC
2.45M
3.34%
--
--
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Genomics Immunology and Healthcare ETF
2.09%
Tema Oncology ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
Invesco NASDAQ Future Gen 200 ETF
0.97%
Invesco S&P SmallCap Health Care ETF
0.64%
ALPS Medical Breakthroughs ETF
0.43%
State Street SPDR S&P Biotech ETF
0.33%
Inspire Small/Mid Cap ESG ETF
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
더 보기
iShares Genomics Immunology and Healthcare ETF
비율2.09%
Tema Oncology ETF
비율1.16%
Virtus LifeSci Biotech Clinical Trials ETF
비율1.06%
Invesco NASDAQ Future Gen 200 ETF
비율0.97%
Invesco S&P SmallCap Health Care ETF
비율0.64%
ALPS Medical Breakthroughs ETF
비율0.43%
State Street SPDR S&P Biotech ETF
비율0.33%
Inspire Small/Mid Cap ESG ETF
비율0.3%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.15%
ProShares Ultra Nasdaq Biotechnology
비율0.15%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
